Amongst multiple companies active in the healthcare sector, Propanc Health Group Corp (OTCMKTS:PPCH) is one of the fastest growing companies. It mainly focuses on developing various treatments for cancer patients. As per the reports, it recently announced that it had come across new insights into the spread and development of carcinomas.
What’s Ahead Now:
A team of researchers from the University of Glasgow published these new findings in the development cycle of carcinomas in British Journal of Cancer. There are high probabilities that these findings may have a positive impact on the lead product of Propanc, named PRP. As per the reports, most of the cancer patients die due to metastasis, which is a prominent cancer spread. If everything goes fine, then PRP can be used as an innovative way to control metastasis.
Lead author of this study Laura Machesky described in her article that tight control on migration and cell growth could present diverse problems when normal pathways are disrupted. As per the data made public by her, control on cell growth and migration is needed to develop and maintain healthy tissues.
The cancer that takes place from these epithelial tissues affects organs and body’s internal surface. This type of cancer is described as carcinomas in medical books.
Even though it has many negative effects on the human body, but one of the most aggressive effects is the loss of epithelial integrity, which is also known as the epithelial to mesenchymal transition. When cancer cells become invasive and motile, they seed new tumors and take control over the entire body within no time.
If Propanc’s study on the development of carcinomas can be carried forward in the right direction, then medical science can find new ways to control this deathly disease in the near future. The management of the company clarified that Propanc would enhance its efforts and try to come up with a suitable solution as soon as possible.